Antibody Firm Affomix to Collaborate with U of Montreal's PGx Centre on Heart Disease Biomarkers

The company will be using its automated, high-throughput monoclonal antibody selection technology to produce several antibodies for each protein target chosen by PGx Centre researchers, enabling them to undertake quantitative, multiplexed profiling of the putative biomarkers.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.